ArticleClinical ophthalmology (Auckland, N.Z.)2025
Expert Opinion to Optimize Clinical Outcomes of Bimatoprost Intracameral Implant Treatment.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving a target intraocular pressure (IOP) in patients with ocular hypertension and open-angle glaucoma has many barriers, some treatment specific and others patient specific. Nonadherence to IOP-lowering eyedrops is one of the major barriers to effective glaucoma treatment. There is a wide range of patients who may benefit from non-topical treatment modalities such as selective laser trabeculoplasty and sustained-release drug delivery, including those who face challenges with topical eyedrops, and those who find benefit in independence from daily medication administration. Sustained-release drug delivery options for lowering IOP include the bimatoprost intracameral implant 10 µg (Bim-I), a relatively new treatment option. This article provides expert opinion on the use of the implant based on available literature, supplementary analysis of clinical trial data, and the experience of the authors who have performed thousands of Bim-I administrations. A single administration of Bim-I has demonstrated the potential to reduce IOP and the need for topical IOP-lowering medication for up to 2 years. Evidence suggests that the safety profile of the implant is most favorable in patients with wide-open (Shaffer grade 4) angles. Recommendations regarding the administration procedure and patient follow-up are provided. The objective of this expert opinion is to help optimize patient selection for Bim-I administration, the implantation procedure, follow-up management, and clinical outcomes while minimizing and addressing potential complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.